Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:
- 8/7/2019 – Alnylam Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $126.00 to $124.00. They now have an “overweight” rating on the stock.
- 8/7/2019 – Alnylam Pharmaceuticals had its price target lowered by analysts at Cowen Inc from $147.00 to $120.00. They now have an “outperform” rating on the stock.
- 8/7/2019 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $125.00 price target on the stock.
- 8/1/2019 – Alnylam Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
Shares of NASDAQ:ALNY traded up $0.23 during trading on Thursday, hitting $83.60. 5,544 shares of the company’s stock were exchanged, compared to its average volume of 730,211. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.28 and a quick ratio of 6.16. Alnylam Pharmaceuticals, Inc. has a 52-week low of $60.27 and a 52-week high of $124.21. The business’s 50-day simple moving average is $76.16 and its 200 day simple moving average is $78.84. The company has a market cap of $9.23 billion, a price-to-earnings ratio of -11.04 and a beta of 2.46.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The firm had revenue of $38.20 million during the quarter, compared to analysts’ expectations of $42.24 million. During the same quarter last year, the business posted ($1.61) earnings per share. The firm’s revenue was up 27.8% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -8.21 EPS for the current fiscal year.
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Recommended Story: What are the risks of holding treasury bonds?
Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.